All Type of News
Who will take Korean distribution licenses for Sovaldi and Harvoni?
The pharmaceutical distribution industry has shown high interests in the Korean distribution licenses of chronic hepatitis C treatments, ‘Sovaldi’ and ‘Harvoni’ that are indicated as products with extremely low margin...
Hanmi, “We will take actions if necessary in accordance with investigation result”Hanmi Pharm announced the company will take an action for investors’ losses generated by the delayed notice if necessary.
At the National Assembly’s National Inspection for the...
|
Hanmi, “Delayed notice was not by intention, but immaturity of work”In terms of the delayed notice of the unfavorable information, Hanmi Pharm President Kwan-Soon Lee claimed the company had no intention, but it was just caused by immaturity of ...
|
Trade deficits on drugs were increased after Korea-US FTA
After the Korea-US FTA, deficits increased in the healthcare industry. Particularly, deficits in the pharmaceutical industry remained the same.
According to the ‘Healthcare Industry’s Imports and Exports with the U.S...
Implementation of ‘innovative drug’ approval system
At the 46th Cabinet meeting hosted by Prime Minister Kyo-Ahn Hwang on the 18th of October, the Ministry of Food and Drug Safety(Minister Moon-Ki Sohn) announced treatment options for patients suffering from life-threa...
Celltrion Healthcare decides to launch Remsima with Pfizer on November
Celltrion Healthcare announced it confirmed the release of Remsima(U.S. product name: Inflectra) with the U.S. exclusive distribution partnering company Pfizer in the world’s largest biomedicine market, the U.S., on N...
Boryun-Roche target anticancer market togetherBoryung Pharm and Roche will target the anticancer market with hands together.
According to the industry concerned on the 18th, Boryung Pharm was known to jointly sell the Roch...
|
Sanofi’s labor-management conflict rises again after NLRC’s rulingThe management-labor conflict of Sanofi-Aventis Korea over the CP violation committed by medical representatives is rising again.
As the Seoul Regional Labor Relations Commiss...
|
How much Celltrion’s ‘Remsima’ is prescribed in Europe?It was observed the collective number of patients prescribed for the Celltrion’s autoimmune disease treatment ‘Remsima(U.S. Johnson & Johnson’s ‘Remicade’ biosimilar)’ is about ...
|
Mundipharma appoints Myung-Sae Lee as new CEOMundipharma Korea announced appointment of President Myung-Sae Lee as the new CEO as of today.
Appointed as the new CEO of Mundipharma Korea, President Myung-Sae Lee used to b...
|
